I am a
Home I AM A Search Login

Papers of the Week

2022 Sep 11




Study protocol for a randomised controlled trial of diacerein versus placebo to treat knee osteoarthritis with effusion-synovitis (DICKENS).


Cai G, Jones G, Cicuttini FM, Wluka AE, Wang Y, Hill C, Keen H, Antony B, Wang X, de Graaff B, Thompson M, Winzenberg T, Buttigieg K, Aitken D
Trials. 2022 Sep 11; 23(1):768.
PMID: 36089595.


There is an unmet need for treatments for knee osteoarthritis (OA). Effusion-synovitis is a common inflammatory phenotype of knee OA and predicts knee pain and structural degradation. Anti-inflammatory therapies, such as diacerein, may be effective for this phenotype. While diacerein is recommended for alleviating pain in OA patients, evidence for its effectiveness is inconsistent, possibly because studies have not targeted patients with an inflammatory phenotype. Therefore, we will conduct a multi-centre, randomised, placebo-controlled double-blind trial to determine the effect of diacerein on changes in knee pain and effusion-synovitis over 24 weeks in patients with knee OA and magnetic resonance imaging (MRI)-defined effusion-synovitis.